Replies to post #100019 on Biotech Values

[DewDiligence]

I think you’re taking my reply to Bladerunner out of context. Bladerunner’s argument, which I find no support for, is that the governing statutes forbid the the FDA from evaluating immunogenicity data in the review of an ANDA.